US EditionNovo Nordisk, U.S. Biotech Company Team up to Create Obesity Pills
- Novo Nordisk, a Danish drugmaker, partnered with California-based Septerna on May 16, 2025, to develop new oral obesity pills.
- The collaboration follows Novo Nordisk’s aim to target GPCR proteins to create pills against obesity, type 2 diabetes, and metabolic diseases.
- The deal includes over $200 million upfront payments and could total $2.2 billion, covering four programs targeting GLP-1, GIP, and glucagon receptors.
- Septerna’s stock rose 69%, while Novo Nordisk’s shares increased by 1.2%. Marcus Schindler, Novo’s chief scientific officer, expressed enthusiasm about advancing oral small molecule drugs that target several different receptors.
- The partnership aims to advance Novo Nordisk’s oral obesity pipeline and respond to a market dominated by injectable therapies, potentially expanding convenient treatment options.
Insights by Ground AI
Does this summary seem wrong?
62 Articles
62 Articles
In a new strategic movement that consolidates its leadership in the obesity market, Novo Nordisk has announced an agreement for $2.2 billion with the biotechnology company Septerna, based in San Francisco, for the development of anti-obesity pills. According to the original report, this agreement reflects the efforts of the Danish pharmaceutical company to remain a benchmark in this highly competitive market. Through this exclusive collaboration…
Coverage Details
Total News Sources62
Leaning Left5Leaning Right11Center11Last UpdatedBias Distribution41% Center, 41% Right
Bias Distribution
- 41% of the sources are Center, 41% of the sources lean Right
41% Right
L 19%
C 41%
R 41%
Factuality
To view factuality data please Upgrade to Premium
